Ghent University Academic Bibliography

Advanced

Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens

Pieternella Lugtenburg, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens UGent, Wanda Krall, Kate Bendall, Zsolt Szabo and Ulrich Jaeger (2012) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 12(5). p.297-305
abstract
Improving the management of elderly patients with lymphoma is of increasing relevance. One thousand one hundred thirteen patients with diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisone) in an observational study. Both older and younger patients failed to receive growth factor support in accordance with international guidelines; patients 65 years and older were more susceptible to febrile neutropenia (FN) and its consequences. Better application of guidelines could reduce rates of FN and improve outcomes.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Dose-dense, Chemotherapy, Filgrastim, Guidelines, Pegfilgrastim, NON-HODGKINS-LYMPHOMA, CLINICAL-PRACTICE, INTERMEDIATE-GRADE, CHEMOTHERAPY, PEGFILGRASTIM, CYCLOPHOSPHAMIDE, PROPHYLAXIS, VINCRISTINE, DOXORUBICIN, RITUXIMAB
journal title
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Clin. Lymphoma Myeloma Leuk.
volume
12
issue
5
pages
297 - 305
Web of Science type
Article
Web of Science id
000310037100002
JCR category
HEMATOLOGY
JCR impact factor
1.667 (2012)
JCR rank
48/66 (2012)
JCR quartile
3 (2012)
ISSN
2152-2650
DOI
10.1016/j.clml.2012.06.004
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
3079569
handle
http://hdl.handle.net/1854/LU-3079569
date created
2012-12-27 15:41:26
date last changed
2016-12-19 15:46:26
@article{3079569,
  abstract     = {Improving the management of elderly patients with lymphoma is of increasing relevance. One thousand one hundred thirteen patients with diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisone) in an observational study. Both older and younger patients failed to receive growth factor support in accordance with international guidelines; patients 65 years and older were more susceptible to febrile neutropenia (FN) and its consequences. Better application of guidelines could reduce rates of FN and improve outcomes.},
  author       = {Lugtenburg, Pieternella and Salar Silvestre, Antonio and Rossi, Francesca G and Noens, Lucien and Krall, Wanda and Bendall, Kate and Szabo, Zsolt and Jaeger, Ulrich},
  issn         = {2152-2650},
  journal      = {CLINICAL LYMPHOMA MYELOMA \& LEUKEMIA},
  keyword      = {Dose-dense,Chemotherapy,Filgrastim,Guidelines,Pegfilgrastim,NON-HODGKINS-LYMPHOMA,CLINICAL-PRACTICE,INTERMEDIATE-GRADE,CHEMOTHERAPY,PEGFILGRASTIM,CYCLOPHOSPHAMIDE,PROPHYLAXIS,VINCRISTINE,DOXORUBICIN,RITUXIMAB},
  language     = {eng},
  number       = {5},
  pages        = {297--305},
  title        = {Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens},
  url          = {http://dx.doi.org/10.1016/j.clml.2012.06.004},
  volume       = {12},
  year         = {2012},
}

Chicago
Lugtenburg, Pieternella, Antonio Salar Silvestre, Francesca G Rossi, Lucien Noens, Wanda Krall, Kate Bendall, Zsolt Szabo, and Ulrich Jaeger. 2012. “Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP Regimens.” Clinical Lymphoma Myeloma & Leukemia 12 (5): 297–305.
APA
Lugtenburg, P., Salar Silvestre, A., Rossi, F. G., Noens, L., Krall, W., Bendall, K., Szabo, Z., et al. (2012). Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 12(5), 297–305.
Vancouver
1.
Lugtenburg P, Salar Silvestre A, Rossi FG, Noens L, Krall W, Bendall K, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2012;12(5):297–305.
MLA
Lugtenburg, Pieternella, Antonio Salar Silvestre, Francesca G Rossi, et al. “Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP Regimens.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 12.5 (2012): 297–305. Print.